Female sex and oral contraceptive use accelerate nicotine metabolism

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 5, 2006, Pages 480-488

  Benowitz, Neal L ^a,b   Lessov Schlaggar, Christina N ^a,b   Swan, Gary E ^a,b   Jacob III, Peyton ^a,b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; DEUTERIUM; ESTROGEN; NICOTINE; PROGESTERONE; SEX HORMONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MENOPAUSE; METABOLISM; NORMAL HUMAN; ORAL CONTRACEPTION; PLASMA CLEARANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REGISTER; SEX DIFFERENCE; SIBLING; STATISTICAL SIGNIFICANCE; TWINS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; COTININE; DEUTERIUM; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MENOPAUSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NICOTINE; SEX FACTORS; SMOKING; TWINS;

EID: 33646475252     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.01.008     Document Type: Article

References (39)

1. Zang E.A., and Wynder E.L. Differences in lung cancer risk between men and women. examination of the evidence. J Natl Cancer Inst 88 (1996) 183-192
2. Thun M.J., Henley S.J., and Calle E.E. Tobacco use and cancer. an epidemiologic perspective for geneticists. Oncogene 21 (2002) 7307-7325
3. Henschke C.I., and Miettinen O.S. Women's susceptibility to tobacco carcinogens. Lung Cancer 43 (2004) 1-5
4. Dempsey D., Jacob III P., and Benowitz N.L. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 301 (2002) 594-598
5. Tyndale R.F., and Sellers E.M. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 24 (2002) 163-171
6. Swan G.E., Benowitz N.L., Jacob III P., Lessov C.N., Tyndale R.F., Wilhelmsen K., et al. Pharmacogenetics of nicotine metabolism in twins. methods and procedures. Twin Res 7 (2004) 435-448
7. Swan G.E., Benowitz N.L., Lessov C.N., Jacob III P., Tyndale R.F., and Wilhelmsen K. Nicotine metabolism. the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 15 (2005) 115-125
8. Jacob III P., Benowitz N.L., and Shulgin A.T. Synthesis of optically pure deuterium-labeled nicotine, nornicotine and cotinine. J Labelled Comp Radiopharm 25 (1988) 1117-1128
9. Jacob III P., and Benowitz N.L. Pharmacokinetics of (S)-nicotine and metabolites in humans. In: Gorrod J.W., and Wahren J. (Eds). Nicotine and related alkaloids. absorption, distribution, metabolism and excretion (1993), Chapman & Hall, London 197-218
10. Jacob III P., Yu L., Wilson M., and Benowitz N.L. Selected ion monitoring method for determination of nicotine, cotinine, and deuterium-labeled analogs. Absence of an isotope effect in the clearance of (S)-nicotine-3'-3'-d2 in humans. Biol Mass Spectrom 20 (1991) 247-252
11. Jacob III P., Yu L., and Benowitz N.L. Determination of nicotine, its major metabolites, and deuterium-labeled isotopomers in human urine using LC-MS/MS. [abstract]. Drug Metab Rev 34 (2002) 160
12. Jacob III P., Shulgin A.T., Yu L., and Benowitz N.L. Determination of the nicotine metabolite trans-3'-hydroxycotinine in smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J Chromatogr 583 (1992) 145-154
13. Perez-Stable E.J., Herrera B., Jacob III P., and Benowitz N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280 (1998) 152-156
14. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24 (1996) 1212-1217
15. Messina E.S., Tyndale R.F., and Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282 (1997) 1608-1614
16. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277 (1996) 1010-1015
17. Dempsey D., Tutka P., Jacob III P., Allen F., Schoedel K., Tyndale R.F., et al. Nicotine metabolite ratio as an index of CYP2A6 metabolic activity. Clin Pharmacol Ther 76 (2004) 64-72
18. Huber P.J. The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium in Mathematical Statistics and Probability (1967), University of California Press, Berkeley (CA) 221-233
19. White H. A heteroscedasticity-consistent covariance matrix estimator and a direct test for heteroscedasticity. Econometrica 48 (1980) 817-830
20. Stata statistical software 2001. release 7.0. College Station (TX): StataCorp; 2001.
21. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence. a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
22. Hukkanen J., Gourlay S.G., Kenkare S., and Benowitz N.L. Influence of menstrual cycle on CYP2A6 activity and cardiovascular effects of nicotine. Clin Pharmacol Ther 77 (2004) 159-169
23. Abernethy D.R., Greenblatt D.J., Divoll M., Arendt R., Ochs H.R., and Shader R.I. Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. N Engl J Med 306 (1982) 791-792
24. Roberts R.K., Grice J., McGuffie C., and Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 101 (1983) 821-825
25. Legler U.F., and Benet L.Z. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther 39 (1986) 425-429
26. Balogh A., Klinger G., Henschel L., Borner A., Vollanth R., and Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 48 (1995) 161-166
27. Slayter K.L., Ludwig E.A., Lew K.H., Middleton Jr. E., Ferry J.J., and Jusko W.J. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 59 (1996) 312-321
28. Laine K., Tybring G., and Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68 (2000) 151-159
29. Mitchell M.C., Hanew T., Meredith C.G., and Schenker S. Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. Clin Pharmacol Ther 34 (1983) 48-53
30. Stoehr G.P., Kroboth P.D., Juhl R.P., Wender D.B., Phillips J.P., and Smith R.B. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 36 (1984) 683-690
31. Miners J.O., Grgurinovich N., Whitehead A.G., Robson R.A., and Birkett D.J. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 22 (1986) 135-142
32. Benowitz N.L., and Hatsukami D. Gender differences in the pharmacology of nicotine addiction. Addict Biol 3 (1998) 383-404
33. Zeman M.V., Hiraki L., and Sellers E.M. Gender differences in tobacco smoking. higher relative exposure to smoke than nicotine in women. J Womens Health Gend Based Med 11 (2002) 147-153
34. Gourlay S.G., Forbes A., Marriner T., Pethica D., and McNeil J.J. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ 309 (1994) 842-846
35. Bjornson W., Rand C., Connett J.E., Lindgren P., Nides M., Pope F., et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health 85 (1995) 223-230
36. Swan G.E., Jack L.M., and Ward M.M. Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction 92 (1997) 207-217
37. Hatsukami D.K., Skoog K., Allen S., and Bliss R. Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Exp Clin Psychopharmacol 3 (1995) 163-173
38. Xu C., Goodz S., Sellers E.M., and Tyndale R.F. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 54 (2002) 1245-1256
39. Smith G.B., Bend J.R., Bedard L.L., Reid K.R., Petsikas D., and Massey T.E. Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos 31 (2003) 1134-1141